TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-5.03%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.81B
AUM Growth
+$1.81B
(+20%)
Cap. Flow
+$415M
Cap. Flow
% of AUM
22.93%
Top 10 Holdings %
Top 10 Hldgs %
39.2%
Holding
208
New
25
Increased
77
Reduced
32
Closed
6
Top Buys
| 1 |
Dynavax Technologies
DVAX
|
$50.6M |
| 2 |
Galapagos
GLPG
|
$45.2M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$33.1M |
| 4 |
Spyre Therapeutics
SYRE
|
$33.1M |
| 5 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.6M |
| 2 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
$7.23M |
| 3 |
GRAL
GRAIL, Inc. Common Stock
GRAL
|
$4.82M |
| 4 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$4.72M |
| 5 |
Seer Inc
SEER
|
$1.52M |
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Technology | 1.25% |
| 3 | Communication Services | 1.23% |
| 4 | Consumer Discretionary | 0.99% |
| 5 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Mineralys Therapeutics
MLYS
$1.94B
| $3.18M | 0.18% |
+200,000
| New | +$3.18M |
|
|
TECX
102
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $3.17M | 0.18% |
179,166
+100,000
| +126% | +$1.77M |
|
|
KLRS
103
Kalaris Therapeutics, Inc. Common Stock
KLRS
$85.5M
| $2.48M | 0.14% |
309,221
-243,043
| -44% | +$2.29M |
|
104
Syndax Pharmaceuticals
SNDX
$1.39B
| $2.46M | 0.14% |
200,000
+100,000
| +100% | +$1.23M |
|
105
Zentalis Pharmaceuticals
ZNTL
$123M
| $2.39M | 0.13% |
+1,500,000
| New | +$2.39M |
|
106
Theravance Biopharma
TBPH
$691M
| $2.35M | 0.13% |
262,896
| – | – |
|
107
Berkshire Hathaway Class B
BRK.B
$1.08T
| $2.34M | 0.13% |
4,401
+1,302
| +42% | +$693K |
|
108
MindMed
MNMD
$689M
| $2.34M | 0.13% |
400,200
+200,200
| +100% | +$1.17M |
|
109
Visa
V
$681B
| $2.3M | 0.13% |
6,570
+1,852
| +39% | +$649K |
|
|
110
Seer Inc
SEER
$114M
| $2.19M | 0.12% |
1,294,423
-900,000
| -41% | -$1.52M |
|
111
JPMorgan Chase
JPM
$824B
| $2.17M | 0.12% |
8,854
+2,253
| +34% | +$553K |
|
112
Verizon
VZ
$184B
| $2.14M | 0.12% |
47,153
+16,276
| +53% | +$738K |
|
113
Coca-Cola
KO
$297B
| $2.13M | 0.12% |
29,762
+10,048
| +51% | +$720K |
|
114
Idexx Laboratories
IDXX
$50.7B
| $2.1M | 0.12% |
5,000
| – | – |
|
115
Walmart
WMT
$793B
| $2.09M | 0.12% |
23,802
+6,379
| +37% | +$560K |
|
116
Johnson & Johnson
JNJ
$429B
| $2.03M | 0.11% |
12,243
+4,284
| +54% | +$710K |
|
|
ATYR
117
aTyr Pharma
ATYR
$560M
| $2.03M | 0.11% |
671,134
| – | – |
|
118
Procter & Gamble
PG
$370B
| $2.01M | 0.11% |
11,813
+3,851
| +48% | +$656K |
|
|
ALLK
119
DELISTED
Allakos
ALLK
| $1.98M | 0.11% |
8,693,687
+8,315,135
| +2,197% | +$1.89M |
|
120
Exxon Mobil
XOM
$477B
| $1.97M | 0.11% |
16,597
+5,544
| +50% | +$659K |
|
121
ALX Oncology
ALXO
$54.6M
| $1.97M | 0.11% |
3,158,265
-138,618
| -4% | -$86.4K |
|
|
BLUE
122
DELISTED
bluebird bio
BLUE
| $1.95M | 0.11% |
+400,000
| New | +$1.95M |
|
123
Intel
INTC
$105B
| $1.93M | 0.11% |
84,945
+28,948
| +52% | +$657K |
|
124
UnitedHealth
UNH
$279B
| $1.85M | 0.1% |
3,541
+1,233
| +53% | +$646K |
|
125
Walt Disney
DIS
$211B
| $1.84M | 0.1% |
18,626
+5,531
| +42% | +$546K |
|